. Induction of p21 WAF1/Cip1 mediated by silencing of HDAC4 arrested cancer cell growth in vitro and inhibited tumor growth in an in vivo human glioblastoma model. Thus, HDAC4 could be a useful target for new anti-cancer therapies based on selective inhibition of specific HDACs.
Introduction
Histone deacetylases (HDACs) regulate gene transcription by modifying the acetylation level of histones and non-histone proteins such as transcription factors. Mammalian HDACs are usually subdivided into three classes based on their similarity to yeast HDACs. Class I members (HDAC1, 2, 3, 8 and 11) are homologous to the yeast RPD3 protein. Class II HDACs (HDAC4, 5, 6, 7, 9 and 10) have similarities to yeast HDA1. The third class, the sirtuin proteins, are homologous to the yeast SIR2 protein, require nicotinamide adenine dinucleotide as a cofactor and are insensitive to HDAC inhibitors (de Ruijter et al., 2003; Glozak et al., 2005; Hildmann et al., 2007; Yang and Seto, 2008) .
Global inhibition of HDAC activity has anti-tumor effects in vitro, and numerous HDAC inhibitors are being tested in clinical trials. The recent FDA approval of SAHA (Zolinza) for treatment of cutaneous T-cell lymphoma (Duvic and Vu, 2007a, b) validates the concept of HDAC inhibition in the treatment of cancer. HDAC inhibitors exert multiple and desirable anticancer effects by modulating the expression of the subset of genes involved in the inhibition of tumor cell proliferation, and differentiation, induction of apoptosis and inhibition of angiogenesis (Marks et al., 2004; McLaughlin and La Thangue, 2004; Acharya et al., 2005; Kelly and Marks, 2005; Bolden et al., 2006; Minucci and Pelicci, 2006; Dokmanovic et al., 2007; Rasheed et al., 2007; Xu et al., 2007) .
Among the genes that are consistently upregulated in cancer cells treated with HDAC inhibitors is the cell cycle mediator p21 WAF1/Cip1 Sowa et al., 1997; Archer et al., 1998; Kim et al., 1999; Saito et al., 1999; Sambucetti et al., 1999; Richon et al., 2000; Han et al., 2001; Rocchi et al., 2005) . p21 WAF1/Cip1 arrests cell growth by inhibiting cyclin/Cdk complexes (Xiong et al., 1993) and can act as tumor suppressor gene by negatively regulating the cell cycle. In p21 WAF1/Cip1 -deficient mice, loss of p21 WAF1/Cip1 accelerated the formation of spontaneous tumors (Martin-Caballero et al., 2001) and increased susceptibility to tumorigenesis in response to chemical carcinogens (Wouters et al., 1997; Philipp et al., 1999; Topley et al., 1999; Poole et al., 2004) . Thus, p21 WAF1/Cip1 has many features of a bona fide tumor suppressor gene. p21 WAF1/Cip1 expression is commonly lost in a variety of human cancers and may therefore contribute to tumor progression. As mutations in the coding region of p21 WAF1/Cip1 are rare events in cancer, epigenetic silencing seems to be the main mechanism by which the p21 WAF1/Cip1 gene is downregulated in tumors (Fang and Lu, 2002) . Epigenetic suppression of p21 WAF1/Cip1 is directly linked to HDAC activity, as inhibition of HDAC activities in cancer cells induces transcriptional reactivation of p21 WAF1/Cip1 through hyperacetylation of histones H3 and H4 in the proximal promoter region Richon et al., 2000; Sawa et al., 2004) . In other studies, p21
Waf1/Cip1 induction by HDAC inhibitors was mediated through Sp1 sites through Sp1 family transcription factors, Sp1 and/or Sp3 Sowa et al., 1997 Sowa et al., , 1999 Han et al., 2001; Wilson et al., 2006) . To date, the most common model for p21
WAF1/Cip1 repression in cancer cells is the recruitment of HDACs by Sp1/-Sp3 transcription factors in the proximal promoter region encompassing the Sp1/Sp3 binding sites, which in turn repress p21 WAF1/Cip1 transcription by deacetylating histones H3 and H4. However, a role for p53 in HDAC-associated p21 WAF1/Cip1 expression has also been reported in several human cancer cell lines (Lagger et al., 2003; Luo et al., 2004; Roy et al., 2005; Zhao et al., 2006) .
Regardless of their mechanism of action, HDAC inhibitors induce p21 WAF1/Cip1 in various cancer cell lines. However, most HDAC inhibitors are global and nonspecific for the various HDAC isoforms. Class I HDACs regulate p21 WAF1/Cip1 gene expression (Huang et al., 2005 (Huang et al., , 2006 Wilson et al., 2006; Senese et al., 2007; Spurling et al., 2008) , but it is not known whether other HDACs are involved.
To identify which HDACs regulate p21 WAF1/Cip1 gene expression in cancer cells, we used small interfering RNAs (siRNAs) to target seven class I and class II HDACs (HDACs1-7). We found that silencing of HDAC4 consistently induces expression of p21 WAF1/Cip1 in various human cancer cell lines. We also demonstrated that induction of p21 WAF1/Cip1 is an important component of inhibition of cancer cell proliferation in vitro and arrest of tumor growth in vivo mediated by silencing of HDAC4, arguing that HDAC4 is a potential target for anticancer therapies.
Results

HDAC4 silencing induces expression of p21
WAF1/Cip1 mRNA and protein HDAC inhibitors induce p21 WAF1/Cip1 in many cancer cell lines Sowa et al., 1997; Archer et al., 1998; Kim et al., 1999; Sambucetti et al., 1999; Han et al., 2000; Huang and Pardee, 2000; Richon et al., 2000; Sawa et al., 2004; Rocchi et al., 2005) and inhibit class I and class II HDACs equally well. To identify the specific HDACs that participate in regulating p21 WAF1/Cip1 , we transfected IGROV-1 cells with siRNAs directed against seven class I and II HDACs (HDAC1 through HDAC7) (Supplementary Figure S1A and B) and examined p21 WAF1/Cip1 by real-time polymerase chain reaction (RT-PCR) and western blot analysis. Both HDAC1 and HDAC4 silencing (HDAC4 siRNA no. 1) significantly increased p21 WAF1/Cip1 gene expression both at mRNA and protein level (Figures 1a and b) . However, the combined silencing of HDAC1 and HDAC4 did not show synergy on p21 WAF1/Cip1 induction compared with individual siRNA suggesting that specific HDAC4 inhibition is sufficient to increase p21 WAF1/Cip1 gene expression (Supplementary Figure S2) . To exclude a non-specific effect of HDAC4 siRNA used, we transfected IGROV-1 cells with two siRNAs whose sequences did not overlap with those of the effective HDAC4 siRNA and evaluated p21 WAF1/Cip1 mRNA and protein levels by RT-PCR and western blot analysis (Figures 1c and d) . Transfection with siRNA HDAC4 no. 2, which effectively reduced HDAC4 abundance, also induced p21 WAF1/Cip1 expression. In contrast, siRNA HDAC4 no. 3 which silenced HDAC4 expression less efficiently was also less efficient in increasing p21 WAF1/Cip1 expression. In the subsequent experiment, siRNA HDAC4 no. 2 was used because it did not affect expression levels of the other HDACs (Supplementary Figure S3A and B), suggesting that specific HDAC4 silencing is involved in the induction of p21 WAF1/Cip1 expression. HDAC4 silencing also induced p21 WAF1/Cip1 expression in human cervical cancer HeLa cells (Figure 1e ), glioblastoma U87-MG cells (Figure 1f ) and breast cancer MCF7 cells (Figure 1g ), suggesting that the effect was not cell type specific.
HDAC4 represses p21
WAF1/Cip1 in cancer cells in vitro in a Sp1-dependent manner Although most reports demonstrated that HDAC inhibitors induced p21 WAF1/Cip1 expression in an Sp1/Sp3-dependent manner Sowa et al., 1997 Sowa et al., , 1999 Han et al., 2001; Wilson et al., 2006) , a role for p53 in HDAC-associated p21 WAF1/Cip1 expression has also been reported in several human cancer cell lines (Lagger et al., 2003; Luo et al., 2004; Roy et al., 2005; Zhao et al., 2006) .
To determine the role of p53 and Sp1/Sp3 transcription factors in the activation of p21 WAF1/Cip1 promoter activity after HDAC4 silencing, we used a series of p21 WAF1/Cip1 promoter constructs (Figure 2a ). IGROV-1 cells were transfected with a full-length human p21
promoter luciferase reporter construct (p21-WT) and a p21 WAF1/Cip1 promoter luciferase reporter construct that was mutated in the first (p21-p53 mut1) or second (p21-p53 mut2) p53-binding site. Neither mutation decreased the HDAC4 inhibition-induced increase in the relative luciferase activity of the full-length p21
WAF1/Cip1 promoter. Similarly, the p21-101 vector, which lacks the two p53-binding sites but contains four Sp1-binding sites important for induction of p21 WAF1/Cip1 by HDAC inhibitors Sowa et al., 1997; Wilson et al., 2006) , was strongly activated by HDAC4 inhibition (Figure 2b ). This finding suggests that the Sp1 elements, not the p53-binding sites, are required for the transcriptional activation of p21 WAF1/Cip1 promoter induced by HDAC4 silencing. In addition, these results demonstrated that the basal level of promoter activity was partially inhibited when p53 response elements were 
IGROV-1 s iR N A E G T / E G T s iR N A H D A C 4 / E G T s iR N A H D A C 4 / p 5 3 s iR N A p 5 3 / E G T N o s iR N A p21
HDAC4 p53 N o s iR N A s iR N A S p 1 s iR N A E G T p21
Sp1
Sp3 s iR N A E G T / E G T s iR N A H D A C 4 / E G T s iR N A H D A C 4 / S p 1 s iR N A S p 1 / E G T N o s iR N
IGROV-1 s iR N A E G T / E G T s iR N A H D A C 4 / E G T s iR N A H D A C 4 / p 5 3 s iR N A p 5 3 / E G T N o s iR N A p21
HDAC4 p53 N o s iR N A s iR N A S p 1 s iR N A E G T p21
Sp1
Sp3 s iR N A E G T / E G T s iR N A H D A C 4 / E G T s iR N A H D A C 4 / S p 1 s iR N A S p 1 / E G T N o s iR N A
Figure 3 Sp1 transcription factor is required for p21 WAF1/Cip1 expression mediated by silencing of HDAC4. Saos-2 cells were cotransfected with HDAC4 siRNA and either Sp1 siRNA (a) or p53 siRNA (b). Co-transfection with EGT siRNA was used as a negative control. The protein levels of HDAC4, Sp1, p53 and p21 WAF1/Cip1 were analysed by western blot. Saos-2 cells are p53-null, so an extract of IGROV-1 cells was used as a positive control to detect p53 on the western blot shown in (b). (c and d) IGROV-1 cells were cotransfected with HDAC4 siRNA and either Sp1 siRNA (c) or p53 siRNA (d). Co-transfection with EGT siRNA was used as a negative control. The protein levels of HDAC4, Sp1, p53 and p21 WAF1/Cip1 were analysed by western blot. (e) IGROV-1 cells were transfected with p53 siRNA and p53 and p21 WAF1/Cip1 protein levels were analysed by western blot. (f) IGROV-1 cells were transfected with Sp1 siRNA and Sp1, Sp3 and p21 WAF1/Cip1 protein levels were analysed by western blot.
HDAC4 represses p21WAF1/Cip1 expression in human cancer cells D Mottet et al mutated or deleted, suggesting that p53-binding sites are critical for p21 WAF1/Cip1 basal promoter activity as reported (Tang et al., 1998; Urban et al., 2003) .
To determine which Sp1-binding sites of the promoter region of the p21-101 vector are responsive to HDAC4 silencing, we tested a series of p21 WAF1/Cip1 promoter constructs with mutation in the Sp1 sites. A mutation in the Sp1-3 binding site abolished p21 WAF1/Cip1 promoter activity mediated by HDAC4 silencing. However, a mutation in the Sp1-4 binding site reduced the activity only partially. Finally, when overlapping Sp1-5/6 binding sites were mutated, HDAC4 silencing did not activate the promoter at all, as the basal promoter activity of p21-101-Sp1-5/6 mut vector was reduced to the background level as reported Sowa et al., 1997; Huang and Pardee, 2000) (Figure 2c ). These findings demonstrate that the Sp1-3 site (À87 and À72 relative to the transcription start site) contains the primary responsive elements for p21 WAF1/Cip1 activation mediated by HDAC4 silencing. The Sp1-4 (À69 and À64 relative to the transcription start site) is also partially involved.
To confirm that Sp1 but not p53 elements are activated by HDAC4 silencing, we used luciferase reporter constructs containing three consensus Sp1 binding sites or 13 consensus p53-binding sites. The silencing of HDAC4 induced expression of Sp1 elements-dependent luciferase (Figure 2d ) but not a p53 elements-dependent luciferase (Figure 2e ), indicating that HDAC4 inhibition-induced p21 WAF1/Cip1 expression was dependent on Sp1 pathway but independent of p53.
Next, we investigated whether HDAC4 silencing induces p21 WAF1/Cip1 expression in a p53-negative human osteosarcoma cell line (Saos-2) (Fogh et al., 1977) . Indeed, p21 WAF1/Cip1 was upregulated. This induction was partly relieved by co-transfection with siRNA-targeting Sp1 (Figure 3a) but not by co-transfection with p53 siRNA (Figure 3b ). Sp1 silencing also prevented the increase in p21 WAF1/Cip1 protein expression induced by HDAC4 silencing in IGROV-1 cells (Figure 3c) . Surprisingly, this increase was also prevented by cotransfection with p53 siRNA (Figure 3d ). Because endogenous p53 regulates the basal expression level of p21 WAF1/Cip1 (Figure 3e ), latter findings probably reflects the decrease in the basal expression level of p21 WAF1/Cip1 induced by the p53-silencing per se. However, as Sp1 silencing did not reduce the constitutive p21 WAF1/Cip1 expression (Figure 3f ), Sp1 is the key transactivator of p21 WAF1/Cip1 expression induced by HDAC4 silencing.
HDAC4 binds the proximal region of the p21 WAF1/Cip1 promoter and deacetylates Histone H3 Next, we investigated the possibility that HDAC4 binds the proximal region of the p21 WAF1/Cip1 promoter containing Sp1/Sp3-binding sites. Chromatin from HDAC4/FLAG-transfected HeLa cells was immunoprecipitated with FLAG or Sp1 antibodies, and precipitated genomic DNA was analysed by PCR with the primers shown in Figure 4a . The association of HDAC4 and Sp1 with the p21 WAF1/Cip1 promoter was detected only with primers encompassing Sp1 sites (Figure 4b ).
To determine whether HDAC4 directly binds the Sp1-3-binding site on the p21 WAF1/Cip1 promoter, we used a 'transient' chromatin immunoprecipitation assay. HeLa cells were co-transfected with a HDAC4/FLAG expression vector and a plasmid containing the wild-type proximal p21 WAF1/Cip1 promoter (p21-101) with or without a mutation in Sp1-3-binding site (p21-101-Sp1-3 mut). Immunoprecipitations were performed with antibodies to FLAG and a control IgG, and PCRs were carried out with primers designed to the vector backbone and luciferase sequences. HDAC4 was recruited to the proximal p21 WAF1/Cip1 promoter but not to the vector backbone (Figure 4c ). The Sp1-3 mutation decreased binding by HDAC4, demonstrating that HDAC4 requires the Sp1-3 binding site to bind the p21 WAF1/Cip1 promoter.
As HDAC inhibitors regulate p21 WAF1/Cip1 gene transcription by modifying histone acetylation in the Kim et al., 1999; Sambucetti et al., 1999; Richon et al., 2000; Sawa et al., 2004) , we used chromatin immunoprecipitation assays to analyse histone H3 acetylation at the Sp1/ Sp3-binding sites-rich region of the p21 WAF1/Cip1 promoter in HDAC4-silenced HeLa cells. Efficient HDAC4-silencing (Figure 4d , left) significantly increased histone H3 acetylation at the p21 WAF1/Cip1 promoter but not at the actin promoter used as a negative control (Figure 4d,  right) . Thus, HDAC4 binds the p21 WAF1/Cip1 promoter region that contains Sp1/Sp3-binding sites and HDAC4-silencing induces p21 WAF1/Cip1 expression, at least in part by a global chromatin remodelling because of accumulation of the acetylated histones H3. Finally, we determined whether HDAC4 associates, directly or indirectly, with Sp1. Endogenous Sp1 was immunoprecipitated from protein lysates of HeLa cells transfected with HDAC4/FLAG with a Sp1-specific antibody and the bound protein complexes were analysed by western blot. Sp1 interacted with HDAC4 and HDAC1 but not with HDAC3 (Figure 4e ), as reported (Doetzlhofer et al., 1999; Sun et al., 2002; Kang et al., 2005; Enya et al., 2008) . Co-immunoprecipitation with anti-FLAG antibody confirmed the physical 
HDAC4 silencing inhibits cell proliferation in vitro and inhibits tumor growth in vivo Because p21
WAF1/Cip1 is a cyclin-dependent kinase inhibitor that blocks the G1/S-phase transition and cell proliferation, the repression of p21 WAF1/Cip1 transcription in cancer cells by HDAC4 suggests a key role for HDAC4 in cancer cells proliferation and tumor growth. To examine the effect of HDAC4 silencing on tumor cell growth, we used an in vivo model in which U87-MG human glioblastoma cells are engrafted onto embryonated chick chorioallantoic membrane. Tumors formed from U87-MG in which HDAC4 was silenced with siRNA ( Figure 5a ) were smaller than those formed in cells that were mock-transfected or transfected with GL3 siRNA (Figures 5b and c) .
We also assessed the effect of HDAC4 silencing on cell cycle progression by flow cytometry. HDAC4 silencing reduced the percentage of S-phase cells, with a concomitant increase in the percentage of G1-phase cells (Figure 5d ). In an in vitro proliferation assay, siRNAinduced silencing of HDAC4 in IGROV-1 decreases the DNA content 72 and 96 h after transfection (Figure 5e ). Similar results were observed in HeLa cells (data not shown).
Induction of p21
WAF1/Cip1 contributes to HDAC4-mediated inhibition of cancer cell proliferation in vitro To investigate the relevance of p21 WAF1/Cip1 induction to the growth arrest after HDAC4 silencing, we cotransfected IGROV-1 cells with siRNAs against p21 WAF1/Cip1 and HDAC4. In cells co-transfected with p21 WAF1/Cip1 and control EGT siRNAs, proliferation rates increased slightly. More importantly, the inhibition of proliferation by HDAC4 silencing was partly relieved by co-transfection with siRNA-targeting p21 WAF1/Cip1 . Thus, the impaired proliferation of HDAC4-silenced IGROV-1 may reflect, at least partly, induction of p21 WAF1/Cip1 expression (Figure 6a ). Examination of p21 WAF1/Cip1 and HDAC4 expression levels at the last time point (72 h) confirmed that HDAC4 siRNA inhibits HDAC4 expression and induces p21 WAF1/Cip1 and, more importantly, that p21 WAF1/Cip1 siRNA downregulates protein and prevents the increase in p21 WAF1/Cip1 expression induced by HDAC4 silencing (Figure 6b) .
To confirm the correlation between HDAC4, p21 WAF1/Cip1 expression and cancer cell proliferation, we examined the effect of HDAC4 overexpression on p21 WAF1/Cip1 expression and cell proliferation. Transfection of IGROV-1 cells with HDAC4/FLAG vector decreased both p21 WAF1/Cip1 protein level (Figure 6c ) and p21 WAF1/Cip1 promoter activity (Figure 6d) , and promoted proliferation, as assessed by measuring DNA content (Figure 6e ).
To conclude, these results show that HDAC4 is a key repressor of p21 WAF1/Cip1 expression and suggest that induction of p21 WAF1/Cip1 is an important component of HDAC4-mediated inhibition of cancer cell proliferation in vitro.
Discussion
In this study, we found that p21 WAF1/Cip1 expression in human cancer cell lines was increased by silencing of HDAC4 and was repressed by HDAC4 through a Sp1-dependent, p53-independent pathway. Overexpression of p21 WAF1/Cip1 mediated by silencing of HDAC4 inhibited cancer cell proliferation in vitro and arrested tumor growth in vivo. Thus, HDAC4 is a key transcriptional regulator in p21 WAF1/Cip1 expression and a potential valuable target for anticancer therapies.
Dissection of the molecular mechanisms of p21
repression by HDAC4 showed that HDAC4 interacts with Sp1, binds the proximal region of the p21 WAF1/Cip1 promoter and deacetylates histone H3, and mainly represses the p21 WAF1/Cip1 promoter through the Sp1/Sp3-binding sites located at À82 relative to transcription start. Previous reports demonstrated that class I HDACs are recruited by Sp1 to the p21 WAF1/Cip1 promoter (Lagger et al., 2002; Huang et al., 2005; Wilson et al., 2006; Senese et al., 2007; Spurling et al., 2008) . Our findings identify HDAC4 as a new component of the Sp1-dependent repressor complex on the p21 WAF1/Cip1 promoter. As HDAC4 alone is enzymatically inactive, it may suppress p21 WAF1/Cip1 transcription by recruiting catalytically active HDACs into transcriptional corepressor complexes such as HDAC3-NCoR/SMRT (Fischle et al., 2002) . While we were preparing this paper, such a model of p21
repression mediated by HDAC4 through association with the catalytically active HDAC3-N-CoR/SMRT corepressor complex has been shown in colon cancer cells (Wilson et al., 2008) . As HDAC3 silencing did not increase p21 WAF1/Cip1 expression in IGROV-1 cells (Figure 1b) , it is also possible that the mechanism by which HDAC4 represses the p21 WAF1/Cip1 promoter varies between cell types. We found that Sp1 physically associates with HDAC4 and HDAC1, but does not interact with HDAC3 as reported (Doetzlhofer et al., 1999; Sun et al., 2002; Davie, 2003; He et al., 2005; Kang et al., 2005) . We therefore speculate that HDAC4 participates, with a HDAC1-dependent co-repressor complex, in p21 WAF1/Cip1 repression. Even if class II HDACs do not seem to participate in class I co-repressor complexes, some reports have shown that HDAC4, HDAC5 and HDAC7 contains class I HDACs, HDAC1, 2 and 3 as well as members of NuRD and Sin3 complexes Kao et al., 2000; Khochbin et al., 2001) . Silencing of HDAC1 in addition to HDAC4 did not synergistically increase p21 WAF1/Cip1 expression (Supplementary Figure S2A) . Thus, HDAC4 may act as a key scaffold protein that recruits and assembles class I HDACs (for example, HDAC1) on the p21 WAF1/Cip1 promoter. If so, silencing of HDAC4 might disrupt the formation of a class I-dependent co-repressor complex on the promoter, and therefore the specific inhibition of HDAC4 rather than global HDAC inhibitor would be sufficient to increase p21 WAF1/Cip1 expression and inhibit tumor growth. However, further investigations remain to be done to fully elucidate the nature of HDAC4-containing repressor complexes on p21 WAF1/Cip1 promoter.
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Previous reports showed that HDAC4 is a key mediator of p53-dependent cancer cell growth arrest in response to DNA damage (Kao et al., 2003; Imbriano et al., 2005; Basile et al., 2006) . Here, we demonstrated that HDAC4 represses p21 WAF1/Cip1 expression in proliferating unstressed cancer cells through a p53-independent mechanism. Thus, HDAC4 may be differentially recruited on p21 WAF1/Cip1 promoter in response to various stimuli and exerts dual antagonist function in cancer cells. Under basal conditions, HDAC4 represses p21 WAF1/Cip1 expression through a Sp1-dependent mechanism and acts as a pro-proliferative factor. In response to DNA-damaging agents, HDAC4 is recruited by p53, which in turn induces p21 WAF1/Cip1 expression to block cancer cell proliferation and mediate the DNA damage repair. In those conditions, HDAC4 acts as an anti-proliferative and a pro-survival factor for cancer cells, indicating that HDAC4 inhibition must be absolutely combined with DNA-damaging agents in conventional chemotherapy for the complete eradication of tumor cells. However, our demonstration that silencing of HDAC4 is sufficient to inhibit cancer cell proliferation in basal conditions is important and suggests that inhibition of HDAC4 could be a useful strategy per se for the treatments of cancer. HDAC4 is expressed in various cultured cancer cell lines and primary tumors (Figures 1 and 2 ; Grozinger and Schreiber, 2000; Lemercier et al., 2002; Kao et al., 2003; Halkidou et al., 2004; Geng et al., 2006) . Even though its expression level is lower in these tumors compared to the corresponding normal tissues (LLeonart et al., 2006) , our findings suggest that the HDAC4 expression level observed in human cancer cell lines is sufficient to repress p21 WAF1/Cip1 . Moreover, our observations that silencing of HDAC4 induces p21 WAF1/Cip1 in various cancer cell lines support the idea that inhibition of HDAC4 could be an effective strategy to treat various types of cancer.
The identification of cancer-related isoforms of HDAC has therapeutic interest in oncology as it might lead to the development of more specific and more efficient HDAC inhibitors with less toxicity and less side effects for patients. Using a small interfering RNA (siRNA) strategy, we have recently observed that specific silencing of HDAC7 led to a similar inhibition of angiogenesis to that observed with non-selective HDAC inhibitors suggesting that HDAC7 is probably the most relevant target(s) for inhibiting angiogenesis, one of the crucial step in cancer development (Mottet et al., 2007) . Here, using a similar approach, we found that silencing of HDAC4 induces expression of p21 WAF1/Cip1 in various human cancer cell lines and decreases cancer cell proliferation in vitro and tumor growth in vivo, arguing perhaps that specific HDAC4 inhibitor could be also directly used as an effective chemotherapeutic molecule in cancer treatment.
Materials and methods
Antibodies
Antibodies against HDAC1, -HDAC3, -HDAC5 and HDAC6 were from Cell Signaling (Danvers, MA, USA). Antibodies against p21
, -HDAC2, -HDAC4 and -HDAC7 were from Santa Cruz Biotechnology. (Santa Cruz, CA, USA). Antibodies against Sp1 were from Santa Cruz Biotechnology or Upstate Biotechnology (Lake Placid, NY, USA). Antibodies against Sp3 were from Abcam (Cambridge, MA, USA). Antibodies against p53 were from BD Pharmingen (San Diego, CA, USA). Antibodies against acetylated histone H3 were from Upstate Biotechnology. Antibodies against b-actin and FLAG epitope were from Sigma (St Louis, MO, USA).
Human cancer cell lines
Ovarian carcinoma (IGROV-1) and glioblastoma (U87-MG) cells were cultured in RPMI-1640 supplemented with 10% fetal bovine serum. Cervical cancer cell lines (HeLa) were maintained in DMEM with 10% fetal bovine serum. Osteosarcoma cells (Saos-2) were grown in McCoy's 5a medium supplemented with 15% fetal bovine serum. All cultures were maintained at 37 1C in a humid 95% air/5% CO 2 chamber.
Plasmids
Vectors used for transfection include p21-WT, p21-p53 mut1 and p21-p53 mut2 (a kind gift from Dr WG Zhu, Department of Biochemistry and Molecular Biology, Peking University Health Science Center, China). The human wild-type p21 WAF1/Cip1 promoter luciferase fusion plasmid, p21-WT, was made from a 2.4-kb genomic fragment of p21 WAF1/Cip1 promoter containing the transcriptional start site, six Sp1-binding sites and two p53-binding sites and subcloned into the luciferase reporter vector pGL3Basic (Promega, Madison, WI, USA). The first p53-binding site, GAACA (À2234 to À2230 relative to the translational start site) was replaced with GAAAC in p21-p53 mut1; the second binding site, AGACT (À1344 to À1340 relative to the translational start site) was replaced with AGAAT in p21-p53 mut2. The p21-101 and p21-101-Sp1-3 mut luciferase reporter vectors were a kind gift from Dr C Seiser (Max F Perutz Laboratories, Medical University of Vienna, Austria). The p21-101-Sp1-4 mut, p21-101-Sp1-5/6 mut and luciferase reporter plasmid Sp1-RE, which contains three consensus Sp1-binding sites were provided by Dr T Sakai (Kyoto Prefectural University of Medicine, Kyoto, Japan). The p53-RE reporter plasmid containing 13 consensus p53-binding sites was kindly provided by Dr C Michiels (URBC, FUNDP, Namur, Belgium). The HDAC4/FLAG construct was generated by cloning the human full-length HDAC4 cDNA in frame with FLAG epitope in pcDNA 3.1 vector (Invitrogen, Carlsbad, CA, USA). 
A siRNA directed against GL3 luciferase, and a negative control siRNA designed by and purchased from Eurogentec (OR-0030-neg05) named EGT siRNA were used as control siRNAs in our small interfering RNA transfection.
HDAC4 represses p21WAF1/Cip1 expression in human cancer cells D Mottet et al
Luciferase assay
Twenty-four hours after siRNA transfection, luciferase reporter plasmids were introduced into cultured cells by Lipofectamine-mediated gene transfer (Invitrogen). The transfection mixture was replaced by regular growth medium 6 h later. Cells were harvested 24 or 48 h later and lysed according to the dual-luciferase assay system (Promega, Madison, USA). Standard firefly and Renilla luciferase activity were serially measured with a luminometer (Lumat LB 9507 model; EG&G Berthold, Bad Wilbad, Germany).
Transfection with siRNA siRNAs were synthesized by Eurogentec (Seraing, Belgium). The sequences of the oligonucleotides are provided in Table 1 . Calcium phosphate-mediated transfections were performed as described earlier (Waltregny et al., 2005) .
Real-time quantitative RT-PCR
The mRNA levels of each HDAC family members and p21
WAF1/Cip1
were assessed by Taqman real-time RT-PCR. Total RNA extraction, cDNA synthesis and PCR conditions were performed as described (Glenisson et al., 2007) . Primer and probe sequences are provided in Table 2 .
Co-immunoprecipitation assay Cells were transfected with DNA (8 mg) for 48 h with Lipofectamine 2000 (Invitrogen) and lysed in buffer consisting of phosphate-buffered saline (PBS), 0.5% (v/v) Triton X-100, 0.5 mM EDTA, 1 mM dithiothreitol and protease inhibitors. After brief sonication, the lysates were incubated with 20 ml of agarose-conjugated FLAG M2 beads (Sigma) for 2 h at 4 1C. Beads were washed extensively with the same buffer, and the complexes were evaluated by western blot.
Western blot analysis Cells were scraped into 1% SDS buffer. Equal amounts of proteins were resolved by SDS-polyacrylamide gel electrophoresis. After transfer and blocking steps, the membranes were probed first with specific primary antibodies and then with HRPconjugated secondary antibodies and developed using a chemiluminescence detection system. b-actin was used as a control.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation assays were performed according to Upstate Biotechnology's procedure with few modifications. For experiments utilizing the p21 WAF1/Cip1 promoter constructs, the assays were performed as described (Lavrrar and Farnham, 2004) .
DNA content measurement assay
After transfection, cells were trypsinized and viable cells were grown for an additional time. Cells were harvested and sonicated in phosphate-buffered saline. Fluorimetric DNA titration was performed as described (Labarca and Paigen, 1980) and used as an indicator of cell density.
Cell cycle analysis by flow cytometry
The relative percentage of cells in each stage of the cell cycle was analysed using the Cycle TEST Plus DNA Reagent Kit (Becton-Dickinson, San Jose, CA, USA), as described by the manufacturer, followed by flow cytometry analysis with FACS Calibur and the ModFit LT program.
Experimental glioma model (chick embryo)
Transfected-U87-MG cells were deposited in plastic rings on chick chorioallantoic membrane at embryonic day 10 as described (Hagedorn et al., 2005) , and monitored for 4-6 days. The tumors were resected, and the volume of the specimen was calculated. Differences in tumor size were analysed by t-test. 
